SHARE AND LOAN NOTE PURCHASE AGREEMENT by and among PRA INTERNATIONAL, a Delaware corporation, as “Buyer Parent,” COLOMERA INVESTMENTS B.V., a Netherlands corporation, as “Buyer,” PBR HOLDINGS SA, a Luxembourg société anonyme, as “Holdings,” OTHER...Share and Loan Note Purchase Agreement • July 26th, 2006 • PRA International • Services-commercial physical & biological research • London
THIS SHARE AND LOAN NOTE PURCHASE AGREEMENT (this “Agreement”), dated as of June 18, 2006, is made by and among PRA International, a Delaware corporation (“Buyer Parent”), Colomera Investments B.V., a Netherlands corporation (“Buyer”), PBR Holdings SA, a Luxembourg société anonyme, (“Holdings”), Stichting Tulip Management, a Dutch foundation (“stichting”) (“Tulip”), W.J. Drijfhout (“Drijfhout”), J.P.M. Hendriks (“Hendriks”), A. van Vliet (“van Vliet”), P. Hollins (“Hollins”, and, together with Drijfhout, Hendriks, and van Vliet, the “Individual Holders,” and each individually an “Individual Holder,” and together with Holdings, the “Sellers,” and each individually a “Seller”), and Pharma Bio-Research Metaholdings B.V., a Netherlands corporation (the “Company”).
AMENDMENT OF THE SHARE AND LOAN NOTE PURCHASE AGREEMENT by and among PRA INTERNATIONAL, a Delaware corporation, as “Buyer Parent,” COLOMERA INVESTMENTS B.V., a Netherlands corporation, as “Buyer,” PBR HOLDINGS SA, a Luxembourg société anonyme, as...Share and Loan Note Purchase Agreement • July 26th, 2006 • PRA International • Services-commercial physical & biological research • England
THIS AMENDMENT OF SHARE AND LOAN NOTE PURCHASE AGREEMENT (this “Amendment Agreement”), dated as of July 21, 2006, is made by and among PRA International, a Delaware corporation (“Buyer Parent”), Colomera Investments B.V., a Netherlands corporation (“Buyer”), PBR Holdings SA, a Luxembourg société anonyme, (“Holdings”), Stichting Tulip Management, a Dutch foundation (“stichting”) (“Tulip”), W.J. Drijfhout (“Drijfhout”), J.P.M. Hendriks (“Hendriks”), A. van Vliet (“van Vliet”), P. Hollins (“Hollins”, and, together with Drijfhout, Hendriks, and van Vliet, the “Individual Holders,” and each individually an “Individual Holder,” and together with Holdings, the “Sellers,” and each individually a “Seller”), and Pharma Bio-Research Metaholdings B.V., a Netherlands corporation (the “Company”).
